Importance of CRT team for optimization of the results: a European point of view

Similar documents
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Large RCT s of CRT 2002 to present

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.

Cardiac Resynchronization ICD Therapy: What is New?

The road to successful CRT implantation: The role of echo

Left Ventricular Ejection Fraction >35%

HF and CRT: CRT-P versus CRT-D

First question: Does CRT Work in AF?

The Role of ICD Therapy in Cardiac Resynchronization

Gender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy

Cardiac Resynchronization Therapy Guidelines and Missing Groups

Cardiac Resynchronization Therapy for Heart Failure

How do I convert my CRT Non Responder into Responder?

How to Use Echocardiography for. Cardiac Resynchronization Therapy WHY TRY TO IMPROVE PATIENT SELECTION FOR CRT? PROSPECT: CRT Response at 6 Months

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Bi-Ventricular pacing after the most recent studies

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure

CRT response: definition and handling of non-responders

CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?

Cardiac Resynchronization Therapy. Michelle Khoo, MD

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Device based CRT optimization: is there a future? Lessons learned from published trials

This is What I do to Improve CRT Response for CRT Non-Responders

BSH Annual Autumn Meeting 2017

Cardiac resynchronization therapy for heart failure: state of the art

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT

I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE

CRT-P or CRT-D From North Alberta to Nairobi

Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing

Site of Latest Mechanical Activation, LV Lead Position and Response to Cardiac Resynchronization Therapy

Do All Patients With An ICD Indication Need A BiV Pacing Device?

La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD

CRT: whom does it benefit?

A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE

The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy

DON T FORGET TO OPTIMISE DEVICE PROGRAMMING

How to Approach the Patient with CRT and Recurrent Heart Failure

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Implantable cardioverter-defibrillators and cardiac resynchronization therapy

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

Heart Failure Overview. Dr Chris K Y Wong

Role of Ablation of AF and PVCs in the Management of Heart Failure

Cardiac Resynchronization Therapy: Improving Patient Selection and Outcomes

Heart Failure Overview. Dr Chris K Y Wong

Three-dimensional Wall Motion Tracking:

WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY?

Cardiac Resynchronization Therapy Selection therapy Echocardiography

Imaging and heart failure

ICD Guidelines: who benefits from an ICD?

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.

Congestive Heart Failure or Heart Failure

Nonpharmacologic Treatment of Ventricular Heart Failure

Newly Diagnosed Heart Failure patient: When to Order an MRI and Why

8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy

Heart failure and sudden death

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure

CRT in the RV Paced Patient When to Upgrade?

14ο Βορειοελλαδικό Καρδιολογικό Συνέδριο ΚΕΒΕ Βηματοδότηση: Νεότερες εξελίξεις Προοπτικές

Cover Page. The handle holds various files of this Leiden University dissertation.

Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients

Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Upgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016

Management of Atrial Fibrillation in Heart Failure

James H. Baker II, MD St. Thomas Heart Nashville, TN

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

EBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA

Impact of QRS duration and morphology on CRT effectiveness

XVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary

Ventricular Arrhythmias

Rational use of imaging for viability evaluation

Interventional solutions for atrial fibrillation in patients with heart failure

Follow-up of CRT patients ESC Munich Clinical and biological follow-up of CRT patients

Why do we need ECHO for CRT device optimization?

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

علم االنسان ما لم يعلم

Novel echocardiographic modalities: 3D echo, speckle tracking and strain rate imaging. Potential roles in sports cardiology. Stefano Caselli, MD, PhD

Device therapy in heartfailure Update of the ESC guidelines. Karl Swedberg

Déclaration de Relations Professionnelles -Disclosure Statement of Financial Interest SPEAKER NAME. Nothing to disclose

Strain Imaging: Myocardial Mechanics Simplified and Applied

Device Therapy for Heart Failure

CRT Vs RV Pacing Benefits

ESC Paris, August 2011

IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE

Cardiac Resynchronization Therapy Optimization Using Trans Esophageal Doppler in Patients with Dilated Cardiomyopathy

Role of CMR in heart failure and cardiomyopathy

Understanding the guidelines for Interventions in MR. Ali AlMasood

Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx

Chapter 25. N Ajmone Marsan, G B Bleeker, R J van Bommel, C JW Borleffs, M Bertini, E R Holman, E E van der Wall, M J Schalij, and J J Bax

Transcription:

Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara

No conflict of interest to declare

No. patients Clinical improvement Echo. improvement PATH-CHF 41 NYHA/QoL/6MWT/less hospitalizations PATH-CHF II 86 QoL/6MWT/less hospitalizations CONTAK-CD 490 NYHA/QoL/6MWT LVEF / LV volumes MUSTIC-SR 58 NYHA/QoL/6MWT/Peak VO 2 /less hospitalizations Ischemic and non-ischemic DCM: MIRACLE 453 NYHA/QoL/6MWT LVEF/LVEDD/MR MIRACLE-ICD 362 NYHA/QoL sinus rhythm Still, (also up to AF) 45% of COMPANION 1520 Reduced all-cause NYHA III-IV (also mortality/hospitalizations non-response II) rate! QRS duration> 120 msec (LBBB) CARE-HF 813 NYHA/QoL/Reduced morbi-mortality LVEF/LVESV PROSPECT 426 Composite (NYHA/hospitalizations/mortality) EF < 35% REVERSE 610 Composite (NYHA/hospitalizations/mortality) LVESV LVESV MADIT-CRT 1820 Reduced all-cause mortality/hospitalizations RAFT 1798 Reduced all-cause mortality/hospitalizations LVEF/LVESV

REASONS FOR FAILURE OF CRT IN HF PTS Dyssynchrony Scar at pacing site Left ventricular lead position Optimization of device setting Optimization of medical therapy Modifiable Older age Total scar burden Impaired renal function Gender Etiology Not modifiable

MODIFIABLE FACTORS Dyssynchrony Scar at pacing site Left ventricular lead position Optimization of device setting Optimization of medical therapy

Mechanical dyssynchrony 95ms

LV Mechanical Dyssynchrony Assessment Echocardiography?? Pitzalis et al. JACC 2002 Bax et al. JACC 2004 Yu et al. Circ 2004 Achilli et al. PACE 2006 Suffoletto et a. Circ 2006 Marsan H&R 2008

MODIFIABLE FACTORS Dyssynchrony Scar at pacing site Left ventricular lead position Optimization of device setting Optimization of medical therapy

Cardiac MRI: scar location LAO Marsan et al. Eur Hear J 2009

MODIFIABLE FACTORS Dyssynchrony Scar at pacing site Left ventricular lead position Optimization of device setting Optimization of medical therapy

Khan FZ et al. J Am Coll Cardiol 2012;59:1509 18

MODIFIABLE FACTORS Dyssynchrony Scar at pacing site Left ventricular lead position Optimization of device setting Optimization of medical therapy

Summary of current evidence for CRT optimization Parameter Standard (current practice) CRT optimization Clinical benefit (compared to standard) AV delay Fixed empirical (100-120 ms) -Echo Doppler -device-based algorithms -mild -mild VV delay Simultaneous BIV -Echo: dyss -Echo: Doppler -ECG -Device-based algorithms -Uncertain -Uncertain -Unknown -Uncertain

What do we do in Ferrara? Multimodality imaging guide LV lead placement

METHODS Observational study Population: 100 HF pts Imaging guided group Control group 50 pts prospectively enrolled, underwent CMR and speckletracking echo pre-crt to guide CRT implant 50 pts retrospectivelyenrolled underwent standard CRT implant Response to CRT: LVESV reduction >15% at 6 month follow-up

METHODS: IMAGING GROUP 1. Standard clinical and echo evaluation: HF specialist 2. CMR imaging: Radiologist and Imaging cardiologist 3. 2D-STE assessment of longitudinal myocardial strain: Imaging cardiologist 4. CRT team (HF specialist, Imaging cardiologist, Electrophysiologist) discussion: Target area 5. CRT Implant: Electrophysiologist

IMAGING GROUP: IDENTIFICATION OF TARGET AREA STEP 1: exclusion of the scar area (area with delayed-enhancement >75%) In patients with non-ischemic cardiomyopathy, area with subepicardial fibrosis, even though non-transmural was also identified and discharged.

a) b) c) Scar Transmurality (%) d) Scar Map Transmural Scar Area Azienda Ospedaliera CARDIAC MRI Universitaria - Ferrara Roma 2015

IMAGING GROUP: IDENTIFICATION OF TARGET AREA STEP 2: 2D ST-Longitudinal strain bull s eye of timings, identification of the most delayed area between non-fibrotic segments

LONGITUDINAL ADVANTAGES OVER THE RADIAL: Timing (ms) 1.MORE REPRODUCIBLE 2.COMPREHENSIVE ASSESSMENT OF THE LV, (AND NOT ONLY OF THE MID-VENTRICLE PORTION) 3.POLAR PLOT MAPS WHICH ARE EASY TO INTERPRET, AVOIDING MEASUREMENTS AND FACILITATING THE COMMUNICATION BETWEEN THE CRT TEAM

IMAGING GROUP: IDENTIFICATION OF TARGET AREA STEP 3: The target area for LV lead position was then defined as the most delayed non-fibrotic area

Ischemic 23 (46%) 24 (48%) Baseline characteristics Imaging-guided Standard practice p value (n = 50) (n = 50) Age (years) 67.3 ± 9.7 65.6 ± 8.4 0.37 Gender (male/female) 37/13 38/12 1 NYHA class 0.19 II, n (%) 29 (58%) 25 (50%) III, n (%) 17 (34%) 24 (48%) IV, n (%) 4 (8%) 1 (2%) QRS duration (ms) 156 ± 24 154 ± 30 0.70 LBBB, n (%) 27 (54%) 26 (52%) 1 Etiology, n (%) 1 Non-ischemic 27 (54%) 26 (52%)

RESULTS IMAGING STANDARD

CRT RESPONSE 15-30% = RESPONDER 0-15% = NON- RESPONDER %ΔESV >30% = SUPER RESPONDER 6m ESV > baseline ESV = NEGATIVE RESPONDER

RESULTS IMAGING STANDARD

TARGET AREA TARGET AREA IS NOT STANDARD BUT IT IS IDEAL AND UNIQUE IN EVERY SINGLE PATIENT!!!

RESULTS WHEN LV LEAD POSITION IS MATCHED WITH TARGET AREA CRT RESPONSE IS HIGHER!!!

Case report:, 60 yrs Cardiologic history: Dilated cardiomyopathy, BBSn, NYHA III, EF 25% No lesion in coronary artery

ΔQRS= -30 msec PRE EF= 25% POST EF= 45%

STUDY LIMITATIONS Non randomized study Control group is retrospective Small sample size CMR limitations (claustrophobia, renal insufficiency, allergics) PROOF OF CONCEPT STUDY

Conclusions Mutlimodality Imaging is: Useful for characterization of myocardial substrate Important for planning implantation strategy Helpful for device setting Crucial for the improvement of response and prognosis

Heart Failure Electrophysiology CRT patient Cardiac Imaging

Traditional Approach to HF Patient HF Clinic EP lab implant Imaging

NEW Approach to HF Patient HF Clinic EP lab implant Imaging Follow up

Thanks!